Immunotherapy | Topics

 
Clinical Activity Reported in Patients With Advanced Solid Tumors Treated With SOT101 Plus Pembrolizumab
April 13, 2022

Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.

Advanced Solid Tumors With High TMB in Both Tissue and Blood Experience Impressive ORR With Nivolumab/Ipilimumab
April 11, 2022

Acceptable efficacy and safety were elicited in patients with advanced solid tumors and high tumor mutational burden detectable in both blood and tissue samples with nivolumab/ipilimumab therapy.

Viability and Future of Maintenance Therapy in Solid Tumors
April 06, 2022

Shilpa Gupta, MD, and Jason R. Brown, MD, PhD, discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Association Found Between Occurrence of Cutaneous Immune-Related AEs and Response to Immunotherapy and Survival
January 14, 2022

Investigators reported that the development of cutaneous immune-related adverse effects has a strong association with response in survival among patients with cancer treated with immunotherapy.

Immune Checkpoint Inhibitors May Be Effective, Safe in Geriatric Cancer
November 24, 2021

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Trial-Ineligible Patients With Advanced Solid Tumors More Likely to Receive Immune Checkpoint Inhibitor Monotherapy
November 17, 2021

Patients with advanced cancers who were ineligible for trials were more likely to receive frontline immune checkpoint inhibitor monotherapy than patients with the same advanced cancers who were eligible for trials.

Clinical Decision-Making in NSCLC
October 25, 2021

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

Role of ctDNA in Monitoring Treatment Response in NSCLC
October 25, 2021

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

Monitoring Response to Therapy in NSCLC
October 18, 2021

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Treatment Options in Non–Small Cell Lung Cancer
October 18, 2021

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.